Abstract
Objective: Ovarian cancer remains the principal cause of gynecologic cancer death worldwide. The standard chemotherapeutic approaches to this cancer are platinum-based chemotherapy (carboplatin and paclitaxel) and bevacizumab (BEV). However, the effects of both platinum-based chemotherapy and BEV on mitochondrial damage in isolated mitochondria from human epithelial ovarian cancers have not yet been investigated. Therefore, the present study aimed to test the hypothesis that platinum-based chemotherapy and BEV equally damage the mitochondria from human epithelial ovarian cancers via increased mitochondrial dysfunction, mitophagy, and mitochondrial apoptosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
